Full Press Release Details
odronextamab receives ema filing acceptance for treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma.
REGN
odronextamab receives ema filing acceptance for treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
Key Takeaway: odronextamab receives ema filing acceptance for treatment of relapsed refractory follicular lymphoma and diffuse large b cell lymphoma